Advertisement

Low IDL-B and high LDL-1 subfraction levels in serum of ALS patients

  • Author Footnotes
    1 Equal contributor.
    J.B. Delaye
    Correspondence
    Corresponding author at: Laboratoire de Biochimie et Biologie moléculaire, Hôpital Bretonneau, CHRU de Tours, 2, Bd Tonnellé, 37044 Tours Cedex 1, France.
    Footnotes
    1 Equal contributor.
    Affiliations
    Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France
    Search for articles by this author
  • Author Footnotes
    1 Equal contributor.
    F. Patin
    Footnotes
    1 Equal contributor.
    Affiliations
    Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France

    Unité Mixte de Recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe « Neurogénétique et Neurométabolomique », 37032 Tours, France
    Search for articles by this author
  • E. Piver
    Affiliations
    Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France

    INSERM U966, Faculté de Médecine, Université François Rabelais and CHRU de Tours, Tours, France
    Search for articles by this author
  • C. Bruno
    Affiliations
    Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France

    Unité Mixte de Recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe « Neurogénétique et Neurométabolomique », 37032 Tours, France
    Search for articles by this author
  • M. Vasse
    Affiliations
    Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France
    Search for articles by this author
  • P. Vourc'h
    Affiliations
    Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France

    Unité Mixte de Recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe « Neurogénétique et Neurométabolomique », 37032 Tours, France
    Search for articles by this author
  • C.R. Andres
    Affiliations
    Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France

    Unité Mixte de Recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe « Neurogénétique et Neurométabolomique », 37032 Tours, France
    Search for articles by this author
  • P. Corcia
    Affiliations
    Unité Mixte de Recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe « Neurogénétique et Neurométabolomique », 37032 Tours, France

    Centre SLA, Service de Neurologie, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France
    Search for articles by this author
  • H. Blasco
    Affiliations
    Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France

    Unité Mixte de Recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe « Neurogénétique et Neurométabolomique », 37032 Tours, France
    Search for articles by this author
  • Author Footnotes
    1 Equal contributor.

      Highlights

      • Lipoprotein levels in ALS results showing low IDL-B and high LDL-1 concentrations.
      • No association between lipoprotein or apolipoprotein levels and clinical findings.
      • There was no difference in the LDL/HDL ratio no association with disease evolution.

      Abstract

      Introduction

      Converging evidence highlights that lipid metabolism plays a key role in ALS pathophysiology. Dyslipidemia has been described in ALS patients and may be protective but peripheral lipoprotein subclasses have never been studied.

      Material and methods

      We collected sera from 30 ALS patients and 30 gender and age-matched controls. We analyzed 11 distinct lipoprotein subclasses by linear polyacrylamide gel electrophoresis (Lipoprint, Quantimetrix Corporation, USA). We also measured lipoprotein (a), apolipoprotein B, and apolipoprotein E levels.

      Results

      ALS patients had significant higher total cholesterol, HDL-cholesterol, and LDL-cholesterol levels than controls (p < 0.0001, p = 0.0007, and p = 0.0065, respectively). The LDL-1 subfraction concentration was higher (1.03 ± 0.41 vs. 0.71 ± 0.28 mmol/L; p = 0.0006) and the IDL-B subfraction lower (6.5 ± 2% vs. 8.0 ± 2%; p = 0.001) in ALS patients than controls.

      Discussion

      Our preliminary work confirmed the association between ALS and dyslipidemia. The low IDL-B levels may explain the hepatic steatosis frequently reported in ALS. The high levels of the cholesterol-rich LDL-1 subfraction is consistent with previously reported hypercholesterolemia.

      Conclusion

      This study describes, for the first time, the distribution of serum lipoproteins in ALS patients, with low IDL-B and high LDL-1 subfraction level.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dupuis L.
        • Pradat P.F.
        • Ludolph A.C.
        • Loeffler J.P.
        Energy metabolism in amyotrophic lateral sclerosis.
        Lancet Neurol. 2011; 10: 75-82
        • Desport J.C.
        • Preux P.M.
        • Magy L.
        • Boirie Y.
        • Vallat J.M.
        • Beaufrere B.
        • et al.
        Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis.
        Am. J. Clin. Nutr. 2001; 74: 328-334
        • Funalot B.
        • Desport J.C.
        • Sturtz F.
        • Camu W.
        • Couratier P.
        High metabolic level in patients with familial amyotrophic lateral sclerosis.
        Amyotroph. Lateral Scler. 2009; 10: 113-117
        • Desport J.C.
        • Torny F.
        • Lacoste M.
        • Preux P.M.
        • Couratier P.
        Hypermetabolism in ALS: correlations with clinical and paraclinical parameters.
        Neurodegener. Dis. 2005; 2: 202-207
        • Kasarskis E.J.
        • Neville H.E.
        Management of ALS: nutritional care.
        Neurology. 1996; 47: S118-120
        • Fergani A.
        • Oudart H.
        • Gonzalez De Aguilar J.L.
        • Fricker B.
        • Rene F.
        • Hocquette J.F.
        • et al.
        Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis.
        J. Lipid Res. 2007; 48: 1571-1580
        • Dupuis L.
        • Corcia P.
        • Fergani A.
        • Gonzalez De Aguilar J.L.
        • Bonnefont-Rousselot D.
        • Bittar R.
        • et al.
        Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.
        Neurology. 2008; 70: 1004-1009
        • Ikeda K.
        • Hirayama T.
        • Takazawa T.
        • Kawabe K.
        • Iwasaki Y.
        Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study.
        Intern. Med. 2012; 51: 1501-1508
        • Chio A.
        • Calvo A.
        • Ilardi A.
        • Cavallo E.
        • Moglia C.
        • Mutani R.
        • et al.
        Lower serum lipid levels are related to respiratory impairment in patients with ALS.
        Neurology. 2009; 73: 1681-1685
        • Yang J.W.
        • Kim S.M.
        • Kim H.J.
        • Kim J.E.
        • Park K.S.
        • Kim S.H.
        • et al.
        Hypolipidemia in patients with amyotrophic lateral sclerosis: a possible gender difference?.
        J. Clin. Neurol. 2013; 9: 125-129
        • Kim S.M.
        • Kim H.
        • Kim J.E.
        • Park K.S.
        • Sung J.J.
        • Kim S.H.
        • et al.
        Amyotrophic lateral sclerosis is associated with hypolipidemia at the presymptomatic stage in mice.
        PLoS One. 2011; 6: e17985
        • Yoshii Y.
        • Hadano S.
        • Otomo A.
        • Kawabe K.
        • Ikeda K.
        • Iwasaki Y.
        Lower serum lipid levels are related to respiratory impairment in patients with ALS.
        Neurology. 2010; 74 (author reply 2027–2028): 2027
        • Murai A.
        • Miyahara T.
        • Tanaka T.
        • Kaneko T.
        • Sako Y.
        • Kameyama M.
        Abnormalities of lipoprotein and carbohydrate metabolism in degenerative diseases of the nervous system—motor neuron disease and spinocerebellar degeneration.
        Tohoku J. Exp. Med. 1983; 139: 365-376
        • Dedic S.I.
        • Stevic Z.
        • Dedic V.
        • Stojanovic V.R.
        • Milicev M.
        • Lavrnic D.
        Is hyperlipidemia correlated with longer survival in patients with amyotrophic lateral sclerosis?.
        Neurol. Res. 2012; 34: 576-580
        • Paganoni S.
        • Deng J.
        • Jaffa M.
        • Cudkowicz M.E.
        • Wills A.M.
        Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis.
        Muscle Nerve. 2011; 44: 20-24
        • Huang R.
        • Guo X.
        • Chen X.
        • Zheng Z.
        • Wei Q.
        • Cao B.
        • Zeng Y.
        • Shang H.
        The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from south-west China and a meta-analysis.
        Amyotroph. Lateral Scler. Frontotemporal Degener. 2015; 16: 359-365
        • Albert S.M.
        Dyslipidemia in ALS: good, bad, or unclear?.
        Neurology. 2008; 70: 988-989
        • Wills A.M.
        • Hubbard J.
        • Macklin E.A.
        • Glass J.
        • Tandan R.
        • Simpson E.P.
        • et al.
        Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.
        Lancet. 2014; 383: 2065-2072
        • Scichilone N.
        • Rizzo M.
        • Benfante A.
        • Catania R.
        • Giglio R.V.
        • Nikolic D.
        • et al.
        Serum low density lipoprotein subclasses in asthma.
        Respir. Med. 2013; 107: 1866-1872
        • Mikhailidis D.P.
        • Elisaf M.
        • Rizzo M.
        • Berneis K.
        • Griffin B.
        • Zambon A.
        • et al.
        “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses.
        Curr. Vasc. Pharmacol. 2011; 9: 533-571
        • Ferrieres J.
        • Lablanche J.M.
        • Pouchain D.
        • Girerd X.
        • Krempf M.
        • Nguyen G.
        • et al.
        Biochemical evaluation of the results of lipid regulating treatment in France.
        Arch. Mal. Coeur Vaiss. 2005; 98: 58-62
        • Patin F.
        • Corcia P.
        • Madji Hounoum B.
        • Veyrat-Durebex C.
        • Respaud E.
        • Piver E.
        • et al.
        Biological follow-up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis.
        Eur. J. Neurol. 2015; 22: 1385-1390
        • Abdel-Khalik J.
        • Yutuc E.
        • Crick P.J.
        • Gustafsson J.A.
        • Warner M.
        • Roman G.
        • et al.
        Defective cholesterol metabolism in amyotrophic lateral sclerosis.
        J. Lipid Res. 2016;
        • Sutedja N.A.
        • van der Schouw Y.T.
        • Fischer K.
        • Sizoo E.M.
        • Huisman M.H.
        • Veldink J.H.
        • et al.
        Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis.
        J. Neurol. Neurosurg. Psychiatry. 2011; 82: 638-642
        • Tribble D.L.
        • Holl L.G.
        • Wood P.D.
        • Krauss R.M.
        Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size.
        Atherosclerosis. 1992; 93: 189-199
        • Mack W.J.
        • Krauss R.M.
        • Hodis H.N.
        Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression.
        Arterioscler. Thromb. Vasc. Biol. 1996; 16: 697-704
        • Hodis H.N.
        • Mack W.J.
        • Dunn M.
        • Liu C.
        • Selzer R.H.
        • Krauss R.M.
        Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness.
        Circulation. 1997; 95: 2022-2026
        • Feingold K.R.
        • Grunfeld C.
        Introduction to Lipids and Lipoproteins.
        2000